| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.79B | 48.58B | 44.26B | 43.32B | 41.88B | 41.20B |
| Gross Profit | 16.81B | 18.91B | 17.10B | 16.67B | 17.66B | 16.07B |
| EBITDA | 6.24B | 7.93B | 7.17B | 6.26B | 7.94B | 7.25B |
| Net Income | 2.29B | 3.18B | 2.48B | 2.22B | 3.25B | 3.12B |
Balance Sheet | ||||||
| Total Assets | 87.48B | 79.86B | 81.16B | 72.05B | 66.45B | 62.61B |
| Cash, Cash Equivalents and Short-Term Investments | 11.66B | 10.77B | 12.96B | 10.49B | 11.45B | 9.45B |
| Total Debt | 9.46B | 8.90B | 9.81B | 11.08B | 7.02B | 8.19B |
| Total Liabilities | 23.81B | 21.32B | 23.71B | 22.16B | 18.54B | 18.96B |
| Stockholders Equity | 52.45B | 48.60B | 47.73B | 42.83B | 41.41B | 38.67B |
Cash Flow | ||||||
| Free Cash Flow | 549.00M | 248.00M | 2.99B | -2.06B | 4.38B | 3.07B |
| Operating Cash Flow | 6.12B | 5.67B | 8.34B | 1.06B | 6.14B | 5.38B |
| Investing Cash Flow | -4.51B | -6.55B | -3.95B | -7.04B | -3.57B | -2.69B |
| Financing Cash Flow | -685.00M | -1.88B | -2.07B | 2.29B | -1.85B | -424.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥42.03B | 15.65 | ― | 1.90% | 2.15% | 16.14% | |
75 Outperform | ¥62.08B | 13.67 | ― | 2.92% | 3.03% | 28.27% | |
74 Outperform | ¥38.97B | 26.79 | ― | 3.24% | 1.83% | -8.54% | |
74 Outperform | ¥42.32B | 5.50 | ― | 3.70% | 14.83% | 51.42% | |
70 Outperform | ¥65.80B | 15.82 | ― | 4.37% | -1.09% | ― | |
67 Neutral | ¥39.05B | 16.63 | ― | 2.37% | -11.70% | -54.82% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
Hodogaya Chemical Co., Ltd. released its consolidated financial results presentation for the third quarter of fiscal year 2025, which ends in March 2026. The materials outline an overview of group performance, segment-by-segment results, and reference indicators such as net sales, operating profit, and EBITDA, signaling continued emphasis on transparency around earnings quality and segment contributions for investors and other stakeholders.
The most recent analyst rating on (JP:4112) stock is a Hold with a Yen2673.00 price target. To see the full list of analyst forecasts on Hodogaya Chemical Co., Ltd. stock, see the JP:4112 Stock Forecast page.
Hodogaya Chemical reported consolidated net sales of ¥34.45 billion for the nine months to December 31, 2025, down 7.5% year on year, with operating profit plunging 47.1% to ¥2.43 billion and profit attributable to owners of parent falling 30.9% to ¥1.99 billion. Despite weaker earnings and a lower equity-to-asset ratio of 60.0%, comprehensive income nearly doubled, and the company maintained its full-year forecast, signaling confidence while forecasting a 3.2% revenue decline and a roughly 28% drop in operating profit for the year to March 31, 2026.
The company plans an annual dividend of ¥50 per share for the fiscal year ending March 31, 2026 on a post-split basis, compared with an effective ¥90 per share in the prior year before a 2-for-1 stock split, pointing to a reduced shareholder payout. Hodogaya also reported an increase in total assets and net assets, minor changes in treasury share levels, and the exclusion of one subsidiary from its consolidation scope, moves that may subtly reshape its balance sheet and group structure without altering its earnings guidance.
The most recent analyst rating on (JP:4112) stock is a Hold with a Yen2673.00 price target. To see the full list of analyst forecasts on Hodogaya Chemical Co., Ltd. stock, see the JP:4112 Stock Forecast page.